Pilot Study Investigating the Use of the ReBuilder to Treat Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02606110

Enrollment

Registered

2015-11-17

Start date

2014-06-30

Completion date

Unknown

Last updated

2017-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Neuropathy

Keywords

ReBuilder, breast cancer, chemotherapy induced

Brief summary

The purpose of this study is to investigate the effect of the ReBuilder in the treatment of individuals with breast cancer and chemotherapy induced peripheral neuropathy.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Patients with breast cancer referred to Physical Therapy for CIPN * Physical Therapy Examination indicates use of Rebuilder for CIPN * At least 18 years of age * Signed informed consent for study population * Willingness to complete study according to protocol

Exclusion criteria

* Patients who do not have CIPN * Patients \<18 years of age * Inability to or unwilling to sign informed consent * Unable to read and understand the English language * Preexisting sensory peripheral neuropathy from other comorbid conditions such as diabetes or alcoholism * More than three (3) prior ReBuilder treatments; OR ReBuilder within the last 30 days, for sensory peripheral neuropathy

Design outcomes

Primary

Measure	Time frame
Changes in touch and sensory by way of change in the Semmes-Weinstein Monofilament Testing	one year
Changes in touch and sensory by way of changes in Functional Gait Assessment	One year

Countries

United States

Outcome results